CTNM Stock Slumps 10% After-Hours — What’s The JNJ Connection?
Contineum said that Johnson & Johnson’s (JNJ) mid-stage trial of JNJ-5120, also known as PIPE-307, failed to meet its main goal in major depressive disorder. The miss is the second mid-stage setback for the same molecule in less than a year. J&J licensed PIPE-307 worldwide in 2023 in a deal that included $50 million upfront, … Read more